SOURCE: BioMedReports


September 09, 2010 05:00 ET

Key Alert: TapImmune Announcements Are a Critical Step in the Company's Development

LOS ANGELES, CA--(Marketwire - September 9, 2010) -  BioMedReports subscribers have been alerted that TapImmune Inc. (OTCBB: TPIV) is starting to pick up momentum as a bottom-up play which features innovative therapeutics and vaccines in the areas of oncology and infectious disease. Their TAP technology deals directly with the cellular arm of the immune system is critical in protecting us against malignant cells that develop into deadly, metastatic cancers.

Shares of this biotechnology company which aims to treat and eradication cancer as well as to prevent infectious disease were up sharply yesterday on rumors that the company would be making some critical changes as they evolve into the next stage of their preclinical and clinical programs. These developments could turn into the next leg-up for the stock, especially if the company's TAP platform proves to be as promising as ABC, BusinessWeek and Popular Mechanics have made it sound when they've covered it.

The stock traded as high as $1.56 during the last 52 weeks, but it finds itself down to mere pennies despite the fact they have announced collaborative agreements with the Mayo Clinic in Breast Cancer and Smallpox recently.

The rumors were confirmed today when the company announced a key appointment to its Board of Directors and Advisory Team.

Dr. Glynn Wilson, the CEO of TapImmune, told BioMedReports that the announcements are a critical step in the company's development.

"The appointment of these renowned individuals to our Board and Advisory Team is a significant step in the building of a world-class group that can advance our technology platform and clinical programs," said Dr. Wilson. "Moreover, it provides endorsement of the strength of our technology and corporate direction. This team will provide immediate support for the exciting partnerships for the treatment of cancer and infectious disease that we have announced over the past few months including two collaborations with the Mayo Clinic and our relationship with Aeras Global TB Vaccine Foundation. These partnerships provide TapImmune with a unique and strong product pipeline addressing unmet clinical needs in multi-billion dollar markets."

From a fundamental analysis perspective, shares may easily continue to rise from these levels if the company starts to push its technology through the regulatory process with the FDA -- as we are hearing they are prepared to do in the weeks and months ahead. The company has far fewer shares outstanding than most companies that trade at these levels, so prices can rise, as they did during yesterday's session rather quickly.

From a technical analysis perspective, the stock appears to have bottomed out and is now starting to pick up more momentum and visibility.

The full commentary and report is available to investors at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556